Table 4. The associations between mTOR rs2536 polymorphism and clinical characteristics of breast cancer patients.
| Variables | TT (%) | TC (%) | P | OR (95% CI) | CC (%) | P | OR (95%CI) | TC + CC (%) | P | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Tumor size | ||||||||||
| < 2 cm | 154 (81.9) | 32 (17.0) | 2 (1.1) | 34 (18.1) | ||||||
| ≥ 2 cm | 299 (80.3) | 68 (18.5) | 0.34 | 1.20 (0.83–1.74) | 5 (1.2) | 0.27 | 0.71 (0.39–1.30) | 66 (19.7) | 0.65 | 1.09 (0.76–1.54) |
| LN metastasis | ||||||||||
| Negative | 190 (80.5) | 43 (18.2) | 3 (1.3) | 46 (19.5) | ||||||
| Positive | 263 (81.1) | 57 (17.6) | 0.276 | 1.22 (0.85–1.73) | 4 (1.3) | 0.1 | 1.67 (0.90–3.10) | 61 (18.9) | 0.14 | 1.29 (0.92–1.80) |
| ER | ||||||||||
| Negative | 200 (80.9) | 44 (17.8) | 3 (1.3) | 47 (19.1) | ||||||
| Positive | 253 (80.8) | 56 (17.9) | 0.126 | 1.32 (0.93–1.87) | 4 (1.3) | 0.916 | 1.03 (0.57–1.86) | 60 (19.2) | 0.18 | 1.26 (0.90–1.76) |
| PR | ||||||||||
| Negative | 209 (82.0) | 43 (16.8) | 3 (1.2) | 46 (18.0) | ||||||
| Positive | 244 (80.2) | 57 (18.6) | 0.414 | 0.86 (0.61–1.23) | 4 (1.2) | 0.461 | 1.25 (0.69–2.28) | 61 (19.8) | 0.64 | 0.92 (0.66–1.29) |
| Her-2 | ||||||||||
| Negative | 312 (80.2) | 72 (18.5) | 5 (1.3) | 77 (19.8) | ||||||
| Positive | 141 (82.4) | 28 (16.3) | 0.299 | 1.22 (0.84–1.79) | 2 (1.3) | 0.292 | 1.39 (0.75–2.60) | 30 (17.6) | 0.22 | 1.25 (0.87–1.80) |
LN, Axillary lymph node; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, human epidermal growth factor receptor 2.